Peter J Schwartz

List of Publications by Year
in descending order

502 papers	63,687 citations	126 h-index	242 g-index
528 all docs	528 docs citations	528 times ranked	24313 citing authors

558

893

#	Article	IF	Citations
1	Outâ€ofâ€hospital cardiac arrest and differential risk of cardiac and nonâ€cardiac QTâ€prolonging drugs in 37â€‰000 cases. British Journal of Clinical Pharmacology, 2022, 88, 820-829.	2.4	7
2	Fear of Sudden Death During Sport Activity and the Long QT Syndrome. , 2022, , 127-137.		0
3	Left Cardiac Sympathetic Denervation for Long QT Syndrome. JACC: Clinical Electrophysiology, 2022, 8, 281-294.	3.2	25
4	Stress, the autonomic nervous system, and sudden death. Autonomic Neuroscience: Basic and Clinical, 2022, 237, 102921.	2.8	10
5	Harmonization of the definition of sudden cardiac death in longitudinal cohorts of the European Sudden Cardiac Arrest network â€“ towards Prevention, Education, and New Effective Treatments (ESCAPE-NET) consortium. American Heart Journal, 2022, 245, 117-125.	2.7	9
6	An International Multicenter Cohort Study on Î²-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2022, 145, 333-344.	1.6	28
7	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
8	Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. European Heart Journal, 2022, 43, 2096-2102.	2.2	22
9	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	1.7	108
10	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.7	78
11	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	1.2	24
12	Molecular genetic testing in athletes: Why and when a position statement from the Italian Society of Sports Cardiology. International Journal of Cardiology, 2022, 364, 169-177.	1.7	6
13	Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?. European Heart Journal, 2022, 43, 3029-3040.	2.2	17
14	MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes. Cardiovascular Research, 2021, 117, 767-779.	3.8	34
15	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	1.7	47
16	NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis. Cardiovascular Research, 2021, 117, 472-483.	3.8	22
17	1970â€“2020: 50 years of research on the long QT syndromeâ€”from almost zero knowledge to precision medicine. European Heart Journal, 2021, 42, 1063-1072.	2.2	26
18	Infanticide vs. inherited cardiac arrhythmias. Europace, 2021, 23, 441-450.	1.7	21

#	Article	IF	Citations
19	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
20	Genetics of Peripartum Cardiomyopathy: Current Knowledge, Future Directions and Clinical Implications. Genes, 2021, 12, 103.	2.4	17
21	Precision Medicine and cardiac channelopathies: when dreams meet reality. European Heart Journal, 2021, 42, 1661-1675.	2.2	34
22	Cadherin 2-Related Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003097.	3.6	21
23	Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726.	4.8	5
24	Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants. Circulation Genomic and Precision Medicine, 2021, 14, e003289.	3.6	10
25	Mutation location and I ÂKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. European Heart Journal, 2021, 42, 4743-4755.	2.2	26
26	Remote Monitoring of the QT Interval and Emerging Indications for Arrhythmia Prevention. Cardiac Electrophysiology Clinics, 2021, 13, 523-530.	1.7	7
27	Long QT syndrome, artificial intelligence, and common sense. European Heart Journal, 2021, 42, 3962-3964.	2.2	16
28	Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19. Frontiers in Physiology, 2021, 12, 730127.	2.8	4
29	Mothers with long QT syndrome are at increased risk for fetal death: findings from a multicenter international study. American Journal of Obstetrics and Gynecology, 2020, 222, 263.e1-263.e11.	1.3	34
30	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi006-A from a patient affected by an autosomal recessive form of long QT syndrome type 1. Stem Cell Research, 2020, 42, 101658.	0.7	4
31	Risk factors for primary ventricular fibrillation during a first myocardial infarction: Clinical findings from PREDESTINATION (PRimary vEntricular fibrillation and suDden dEath during firST) Tj ETQq1 1 0.784314 rgBT /Overlock 10	14	
32	Exercise Training-Induced Repolarization Abnormalities Masquerading as Congenital Long QT Syndrome. Circulation, 2020, 142, 2405-2415.	1.6	36
33	Inherited cardiac arrhythmias. Nature Reviews Disease Primers, 2020, 6, 58.	30.5	146
34	Genotype Predicts Outcomes in Fetuses and Neonates With Severe Congenital Long QT Syndrome. JACC: Clinical Electrophysiology, 2020, 6, 1561-1570.	3.2	24
35	Prevalence and Phenotypic Correlations of Calmodulinopathy-Causative CALM1-3 Variants Detected in a Multicenter Molecular Autopsy Cohort of Sudden Unexplained Death Victims. Circulation Genomic and Precision Medicine, 2020, 13, e003032.	3.6	3
36	SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circulation Genomic and Precision Medicine, 2020, 13, e002911.	3.6	41

#	Article	IF	Citations
37	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
38	Autonomic Control of the Heart and Its Clinical Impact. A Personal Perspective. Frontiers in Physiology, 2020, 11, 582.	2.8	26
39	Abnormal myocardial expression of SAP97 is associated with arrhythmogenic risk. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1357-H1370.	3.2	13
40	The answers to questions surrounding left cardiac sympathetic denervation are in the library, covered by dust. Heart Rhythm, 2020, 17, 1646-1648.	0.7	1
41	Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007471.	4.8	10
42	An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439.	1.6	39
43	There are 100 ways by which the sympathetic nervous system can trigger life-threatening arrhythmias. European Heart Journal, 2020, 41, 2180-2182.	2.2	13
44	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	2.2	15
45	Cardiac Repolarization and Stem Cells: An Emerging Path Toward Precision Medicine. , 2020, , 87-107.		1
46	Drug-Induced Long QT Syndrome and Torsades de Pointes. , 2020, , 185-200.		1
47	Long QT Syndrome. , 2020, , 3-24.		0
48	Neonatal ECG Screening: When Timing Matters. Neonatology, 2020, 117, 764-766.	2.0	0
49	Generation of two human induced pluripotent stem cell (hiPSC) lines from a long QT syndrome South African founder population. Stem Cell Research, 2019, 39, 101510.	0.7	3
50	Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. Circulation Research, 2019, 125, 653-658.	4.5	53
51	Genetic Mosaicism in Calmodulinopathy. Circulation Genomic and Precision Medicine, 2019, 12, 375-385.	3.6	33
52	Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. European Heart Journal, 2019, 40, 2964-2975.	2.2	116
53	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. European Heart Journal, 2019, 40, 2953-2961.	2.2	96
54	When prescribing drugs, do medical doctors and healthcare professionals realize that their patient has the long QT syndrome?. European Heart Journal, 2019, 40, 3118-3120.	2.2	4

#	Article	IF	Citations
55	Physical Inactivity Is a Risk Factor for Primary Ventricular Fibrillation. Journal of the American College of Cardiology, 2019, 73, 2117-2118.	2.8	11
56	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation. Stem Cell Research, 2019, 37, 101437.	0.7	1
57	Mexiletine Shortens the QT Interval in Patients With Potassium Channelâ€“Mediated Type 2 Long QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007280.	4.8	74
58	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene. Stem Cell Research, 2019, 36, 101416.	0.7	2
59	Cardiac Sympathetic Denervation in Channelopathies. Frontiers in Cardiovascular Medicine, 2019, 6, 27.	2.4	25
60	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi004-A from a carrier of the KCNQ1-R594Q mutation. Stem Cell Research, 2019, 37, 101431.	0.7	2
61	From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal, 2019, 40, 1832-1836.	2.2	69
62	Precision Versus Traditional Medicineâ€”Clinical Questions Trigger Progress in Basic Science. Circulation Research, 2019, 124, 459-461.	4.5	5
63	Proarrhythmic proclivity of left-stellate ganglion stimulation in a canine model of drug-induced long-QT syndrome type 1. International Journal of Cardiology, 2019, 286, 66-72.	1.7	17
64	International Triadin Knockout Syndrome Registry. Circulation Genomic and Precision Medicine, 2019, 12, e002419.	3.6	32
65	Cardiac sympathetic denervation via a transtracheal approach: Itâ€™s a long way to Tipperary. Heart Rhythm, 2019, 16, 125-127.	0.7	2
66	Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells. Arrhythmia and Electrophysiology Review, 2019, 8, 105-110.	2.4	36
67	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene. Stem Cell Research, 2018, 29, 157-161.	0.7	3
68	European Sudden Cardiac Arrest network: towards Prevention, Education and New Effective Treatments (ESCAPE-NET). European Heart Journal, 2018, 39, 86-88.	2.2	23
69	Determinants of occurrence and survival after sudden cardiac arrestâ€“A European perspective: The ESCAPE-NET project. Resuscitation, 2018, 124, 7-13.	3.0	33
70	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1. Stem Cell Research, 2018, 29, 170-173.	0.7	6
71	Sudden Infant Death Syndrome andÂGenetics. Journal of the American College of Cardiology, 2018, 71, 1228-1230.	2.8	5
72	Electronic gadgets and their health-related claims. International Journal of Cardiology, 2018, 258, 163-164.	1.7	8

#	Article	IF	Citations
73	Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. European Heart Journal, 2018, 39, 1446-1455.	2.2	100
74	The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?. International Journal of Cardiology, 2018, 250, 139-145.	1.7	42
75	Long and Short QT Syndromes. , 2018, , 893-904.		2
76	Cardiac arrest and Brugada syndrome: Is drug-induced type 1 ECG pattern always a marker of low risk?. International Journal of Cardiology, 2018, 254, 142-145.	1.7	13
77	Alberto Zanchetti. Hypertension, 2018, 72, 786-787.	2.7	0
78	Bongani Mayosi, 1967â€“2018. European Heart Journal, 2018, 39, 4051-4052.	2.2	0
79	Is Careful Assessment of Rare Variants in the RYR2 Gene Piercing the Guidelinesâ€™ Strong Armor?. Circulation Genomic and Precision Medicine, 2018, 11, e002072.	3.6	1
80	Can genetics predict risk for sudden cardiac death? The relentless search for the Holy Grail. European Heart Journal, 2018, 39, 3970-3972.	2.2	8
81	Modifier genes for sudden cardiac death. European Heart Journal, 2018, 39, 3925-3931.	2.2	52
82	For neonatal ECG screening there is no reason to relinquish old Bazettâ€™s correction. European Heart Journal, 2018, 39, 2888-2895.	2.2	28
83	Long QT Syndrome and Sport: My Views. , 2018, , 269-278.		2
84	SCN5A mutations in 442 neonates and children: genotypeâ€“phenotype correlation and identification of higher-risk subgroups. European Heart Journal, 2018, 39, 2879-2887.	2.2	33
85	Letter concerning the editorial by Giustetto et al. Int J Cardiol 2018;254:170â€“171. International Journal of Cardiology, 2018, 268, 155.	1.7	0
86	Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. Heart Rhythm, 2018, 15, 1791-1799.	0.7	77
87	Alberto Zanchetti (27 July 1926). European Heart Journal, 2018, 39, 2344-2345.	2.2	1
88	A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. International Journal of Cardiology, 2018, 266, 89-94.	1.7	53
89	Risk stratification for sudden cardiac death in primary electrical disorders. , 2018, , 2322-2327.		0
90	Monogenic and oligogenic cardiovascular diseases: genetics of arrhythmiasâ€”catecholaminergic polymorphic ventricular tachycardia. , 2018, , .		0

#	Article	IF	Citations
91	Identification of Cadherin 2 (CDH2) Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	123
92	Red BullÂ®: Red flag or red herring?. International Journal of Cardiology, 2017, 231, 179-180.	1.7	3
93	The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. International Journal of Cardiology, 2017, 240, 367-371.	1.7	28
94	Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. International Journal of Cardiology, 2017, 249, 268-273.	1.7	70
95	Patient-Specific Induced Pluripotent Stem Cellâ€“Based Disease Model for Pathogenesis Studies and Clinical Pharmacotherapy. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	10
96	Cardiac sympathetic denervation 100 years later: Jonnesco would have never believed it. International Journal of Cardiology, 2017, 237, 25-28.	1.7	27
97	Reference values of heart rate variability. Heart Rhythm, 2017, 14, 302-303.	0.7	24
98	Founder populations with channelopathies and church records reveal all sorts of interesting secrets: Some are scientifically relevant. Heart Rhythm, 2017, 14, 1882-1883.	0.7	1
99	Evolution in Managing Long QT Syndrome. Journal of the American College of Cardiology, 2017, 70, 463-465.	2.8	1
100	Rationale and design of a prospective study to assess the effect of left cardiac sympathetic denervation in chronic heart failure. International Journal of Cardiology, 2017, 248, 227-231.	1.7	18
101	Channelopathies as Causes of Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 537-549.	1.7	28
102	Regional Lack of Consistency in the Management of Atrial Fibrillation (from the RECORD-AF Trial). American Journal of Cardiology, 2017, 119, 47-51.	1.6	6
103	Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovascular Research, 2017, 113, 531-541.	3.8	110
104	The expression of the rare caveolin-3 variant T78M alters cardiac ion channels function and membrane excitability. Cardiovascular Research, 2017, 113, 1256-1265.	3.8	19
105	Neural and Spinal Stimulation. , 2017, , 595-601.		1
106	Response to Letters Regarding Article, â€œClinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervationâ€• Circulation, 2016, 133, e366-7.	1.6	2
107	Management of survivors of cardiac arrest â€" the importance of genetic investigation. Nature Reviews Cardiology, 2016, 13, 560-566.	13.7	13
108	Response by Crotti et al to Letter Regarding Article, â€œGenetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3â€² Untranslated Region of KCNQ1?â€• Circulation: Cardiovascular Genetics, 2016, 9, 581-582.	5.1	10

#	Article	IF	Citations
109	Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 149-158.	2.8	283
110	Predicting the Unpredictable. Journal of the American College of Cardiology, 2016, 67, 1639-1650.	2.8	227
111	Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes Carrying CALM1-F142l Mutation Recapitulate LQTS Phenotype in Vitro. Biophysical Journal, 2016, 110, 263a.	0.5	0
112	Clinical Aspects of Type 3 Long-QT Syndrome. Circulation, 2016, 134, 872-882.	1.6	162
113	Genetic Modifiers for the Long-QT Syndrome. Circulation: Cardiovascular Genetics, 2016, 9, 330-339.	5.1	21
114	Difficult management of Jervell and Lange-Nielsen syndrome: An endless search. Heart Rhythm, 2016, 13, 2193-2194.	0.7	1
115	Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Scientific Reports, 2016, 6, 22235.	3.3	31
116	When the risk is sudden death, does quality of life matter?. Heart Rhythm, 2016, 13, 70-71.	0.7	14
117	Clinical neurocardiology defining the value of neuroscienceâ€based cardiovascular therapeutics. Journal of Physiology, 2016, 594, 3911-3954.	2.9	222
118	Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm, 2016, 13, 1274-1282.	0.7	89
119	The genetics underlying acquired long QT syndrome: impact for genetic screening. European Heart Journal, 2016, 37, 1456-1464.	2.2	164
120	Vagal Stimulation in Heart Failure: An Anti-inflammatory Intervention?. , 2016, , 165-182.		1
121	Time, frequency and information domain analysis of heart period and QT variability in asymptomatic long QT syndrome type 2 patients. , 2015, 2015, 294-7.		1
122	Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis. PLoS ONE, 2015, 10, e0127213.	2.5	24
123	A Refined Multiscale Self-Entropy Approach for the Assessment of Cardiac Control Complexity: Application to Long QT Syndrome Type 1 Patients. Entropy, 2015, 17, 7768-7785.	2.2	4
124	Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2015, 131, 2185-2193.	1.6	238
125	Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovascular Research, 2015, 106, 520-529.	3.8	108
126	Autonomic Control of Heart Rate and QTÂInterval Variability Influences Arrhythmic Risk in Long QT Syndrome Type 1. Journal of the American College of Cardiology, 2015, 65, 367-374.	2.8	70

#	Article	IF	Citations
127	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine) Tj ETQq1 1 0.784314 rgBT /Over	0.7	63
128	Vox clamantis in deserto. We spoke but nobody was listening: echocardiography can help risk stratification of the long-QT syndrome. European Heart Journal, 2015, 36, 148-150.	2.2	6
129	Reply to the Editorâ€"Detection of long QT syndrome in the community. Heart Rhythm, 2015, 12, e67-e68.	0.7	1
130	Autonomic Modulation for the Management of Patients with Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 619-628.	3.9	54
131	Remodelling of cardiac sympathetic re-innervation with thoracic spinal cord stimulation improves left ventricular function in a porcine model of heart failure. Europace, 2015, 17, 1875-1883.	1.7	28
132	MY APPROACH to the long QT syndrome (LQTS). Trends in Cardiovascular Medicine, 2015, 25, 376-377.	4.9	5
133	Neonatal ECG screening: Opinions and facts. Heart Rhythm, 2015, 12, 610-611.	0.7	8
134	Biventricular arrhythmogenic cardiomyopathy: a paradigmatic case. ScienceOpen Research, 2015, .	0.6	0
135	Multiscale Complexity Analysis of the Cardiac Control Identifies Asymptomatic and Symptomatic Patients in Long QT Syndrome Type 1. PLoS ONE, 2014, 9, e93808.	2.5	35
136	Low-Pass Filtering Approach via Empirical Mode Decomposition Improves Short-Scale Entropy-Based Complexity Estimation of QT Interval Variability in Long QT Syndrome Type 1 Patients. Entropy, 2014, 16, 4839-4854.	2.2	12
137	Filtering approach based on empirical mode decomposition improves the assessment of short scale complexity in long QT syndrome type 1 population. , 2014, 2014, 6671-4.		0
138	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 896-904.	2.2	52
139	Arrhythmogenic Calmodulin Mutations Disrupt Intracellular Cardiomyocyte Ca 2+ Regulation by Distinct Mechanisms. Journal of the American Heart Association, 2014, 3, e000996.	3.7	79
140	A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: Validation of the 2013 diagnostic criteria. Heart Rhythm, 2014, 11, 1176-1183.	0.7	32
141	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 29-47.	1.2	16
142	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 1-28.	1.2	49
143	Left cardiac sympathetic denervation in the Netherlands for the treatment of inherited arrhythmia syndromes. Netherlands Heart Journal, 2014, 22, 160-166.	0.8	59
144	Left Cardiac Sympathetic Denervation in Patients with Heart Failure: a New Indication for an Old Intervention?. Journal of Cardiovascular Translational Research, 2014, 7, 338-346.	2.4	13

#	Article	IF	Citations
145	Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nature Reviews Cardiology, 2014, 11, 346-353.	13.7	183
146	Rationale and objectives for ECG screening in infancy. Heart Rhythm, 2014, 11, 2316-2321.	0.7	57
147	The Role of the Cardiac Sodium Channel in Perinatal Early Infant Mortality. Cardiac Electrophysiology Clinics, 2014, 6, 749-759.	1.7	8
148	Characterization of SEMA3A -Encoded Semaphorin as a Naturally Occurring K v 4.3 Protein Inhibitor and its Contribution to Brugada Syndrome. Circulation Research, 2014, 115, 460-469.	4.5	54
149	AKAP9 Is a Genetic Modifier of Congenital Long-QT Syndrome Type 1. Circulation: Cardiovascular Genetics, 2014, 7, 599-606.	5.1	59
150	Rapid Recovery of Baroreceptor Reflexes in Acute Myocardial Infarction is a Marker of Effective Tissue Reperfusion. Journal of Cardiovascular Translational Research, 2014, 7, 553-559.	2.4	5
151	Risk stratification for sudden cardiac death: current status and challenges for the future. European Heart Journal, 2014, 35, 1642-1651.	2.2	341
152	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	21.4	281
153	Sudden Death by Stress. Journal of the American College of Cardiology, 2014, 63, 828-830.	2.8	6
154	Reply to the Editorâ€" Propranolol Prevents Life-Threatening Arrhythmias in LQT3 Transgenic Mice: Implications for the Clinical Management of LQT3 Patients. Heart Rhythm, 2014, 11, e1-e2.	0.7	4
155	Drug-Induced Long QT Syndrome and Exome Sequencing. Journal of the American College of Cardiology, 2014, 63, 1438-1440.	2.8	4
156	Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: Implications for the clinical management of LQT3 patients. Heart Rhythm, 2014, 11, 126-132.	0.7	34
157	Novel Calmodulin Mutations Associated With Congenital Arrhythmia Susceptibility. Circulation: Cardiovascular Genetics, 2014, 7, 466-474.	5.1	165
158	Genotype-Phenotype Correlation in Induced Pluripotent Stem Cell (iPSC)Derived Cardiomyocytes Carrying Calmodulin Mutations. Biophysical Journal, 2014, 106, 333a.	0.5	1
159	163â€...Genetic Modifiers in Carriers of the SCN5A E1784K Mutation with Variable Phenotypic Expression - Long QT3 / Brugada Syndrome Overlap Disease. Heart, 2014, 100, A94.1-A94.	2.9	0
160	Tumor Necrosis Factor-Î± Predicts Response to Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure. Circulation Journal, 2014, 78, 2232-2239.	1.6	28
161	Long and Short QT Syndromes. , 2014, , 935-946.		3
162	Can we Modulate the Autonomic Nervous System to Improve the Life of Patients with Heart Failure? The Case of Vagal Stimulation. Arrhythmia and Electrophysiology Review, 2014, 3, 120.	2.4	1

#	Article	IF	Citations
163	Long QT Syndromeâ€“Associated Mutations in Intrauterine Fetal Death. JAMA - Journal of the American Medical Association, 2013, 309, 1473.	7.4	140
164	Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nature Genetics, 2013, 45, 1044-1049.	21.4	467
165	Impact of Genetics on the ClinicalÂManagementÂof Channelopathies. Journal of the American College of Cardiology, 2013, 62, 169-180.	2.8	271
166	FGF12 is a candidate Brugada syndrome locus. Heart Rhythm, 2013, 10, 1886-1894.	0.7	94
167	The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. European Heart Journal, 2013, 34, 3109-3116.	2.2	282
168	Calmodulin Mutations Associated With Recurrent Cardiac Arrest in Infants. Circulation, 2013, 127, 1009-1017.	1.6	331
169	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, e85-e108.	0.7	159
170	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, 1932-1963.	0.7	1,587
171	Vagal stimulation for heart diseases: from animals to men. An example of translational cardiology. Netherlands Heart Journal, 2013, 21, 82-84.	0.8	9
172	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace, 2013, 15, 1389-1406.	1.7	494
173	The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace, 2013, 15, 429-436.	1.7	32
174	Refined multiscale entropy analysis of heart period and QT interval variabilities in long QT syndrome type-1 patients. , 2013, 2013, 5554-7.		4
175	Identification of a KCNQ1 Polymorphism Acting as a Protective Modifier Against Arrhythmic Risk in Long-QT Syndrome. Circulation: Cardiovascular Genetics, 2013, 6, 354-361.	5.1	69
176	Congenital Long QT Syndrome. , 2013, , 439-468.		6
177	PREDESTINATION: PRimary vEntricular fibrillation and suDden dEath during a firST myocardIal iNfArcTION: Genetic Basis. Contributions To Statistics, 2013, , 85-96.	0.2	2
178	Practical issues in the management of the long QT syndrome: focus on diagnosis and therapy. Swiss Medical Weekly, 2013, 143, w13843.	1.6	17
179	Cardiac Channelopathies and Sudden Infant Death Syndrome. , 2013, , 381-394.		0
180	Introduction to the Arrhythmogenic Disorders of Genetic Origin Series. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 604-605.	4.8	4

#	Article	IF	Citations
181	Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 868-877.	4.8	498
182	A Novel Disease Gene for Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1098-1107.	4.8	84
183	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2012, 366, 1159-1161.	27.0	5
184	Autonomic modulation for chronic heart failure: a new kid on the block?. European Journal of Heart Failure, 2012, 14, 1316-1318.	7.1	4
185	Dietary Omega-3 Fatty Acids and Susceptibility to Ventricular Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 553-560.	4.8	28
186	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [Europace 2011;13:1077-109, doi: 10.1093/europace/eur245]. Europace, 2012, 14, 277-277.	1.7	1
187	Nadolol Block of Nav1.5 Does Not Explain Its Efficacy in the Long QT Syndrome. Journal of Cardiovascular Pharmacology, 2012, 59, 249-253.	1.9	30
188	Vagal stimulation for the treatment of heart failure: a translational success story. Heart, 2012, 98, 1687-1689.	2.9	18
189	A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na 1.5 and K 4.3 channel currents. Heart Rhythm, 2012, 9, 760-769.	0.7	104
190	When genetic screening for your patient with long QT syndrome comes back negative, donâ€™t always take a no for a no. Heart Rhythm, 2012, 9, 1983-1985.	0.7	0
191	Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. American Heart Journal, 2012, 163, 887-893.	2.7	88
192	Rationale and study design of the INcrease Of Vagal TonE in Heart Failure study: INOVATE-HF. American Heart Journal, 2012, 163, 954-962.e1.	2.7	130
193	Vagal Reflexes Following an Exercise Stress Test. Journal of the American College of Cardiology, 2012, 60, 2515-2524.	2.8	51
194	The Unstoppable Attraction for Induced Pluripotent Stem Cells. Journal of the American College of Cardiology, 2012, 60, 1001-1004.	2.8	7
195	Spectrum and Prevalence of Mutations Involving BrS1- Through BrS12-Susceptibility Genes in a Cohort of Unrelated Patients Referred for Brugada Syndrome Genetic Testing. Journal of the American College of Cardiology, 2012, 60, 1410-1418.	2.8	193
196	Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2. Journal of the American College of Cardiology, 2012, 60, 2092-2099.	2.8	234
197	Torsades de pointes following acute myocardial infarction: Evidence for a deadly link with a common genetic variant. Heart Rhythm, 2012, 9, 1104-1112.	0.7	34
198	The Role of the Sympathetic Nervous System in the Long QT Syndrome: The Long Road from Pathophysiology to Therapy. Cardiac Electrophysiology Clinics, 2012, 4, 75-85.	1.7	6

#	Article	IF	Citations
199	Genetic Diseases. , 2012, , 875-883.		1
200	Abnormal heart rate control in SCN5Aâ€[Delta]KPQ Mice. FASEB Journal, 2012, 26, 1135.4.	0.5	0
201	Transient outward current (Ito) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm, 2011, 8, 1024-1032.	0.7	226
202	Sudden cardiac death, founder populations, and mushrooms: What is the link with gold mines and modifier genes?. Heart Rhythm, 2011, 8, 548-550.	0.7	25
203	Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals. Journal of the American College of Cardiology, 2011, 57, 51-59.	2.8	268
204	Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome. Journal of the American College of Cardiology, 2011, 57, 941-950.	2.8	110
205	Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 493-501.	2.8	159
206	Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome. Heart Rhythm, 2011, 8, 1207-1213.	0.7	22
207	Inherited Cardiac Arrhythmia Syndrome: Role of Potassium Channels. Cardiac Electrophysiology Clinics, 2011, 3, 113-124.	1.7	0
208	High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. International Journal of Cardiology, 2011, 147, 124-131.	1.7	76
209	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	1.7	699
210	Sudden Infant Death Syndrome and Cardiac Channelopathies: From Mechanisms to Prevention of Avoidable Tragedies. Neurology International, 2011, 1, e6.	0.5	5
211	Long QT syndrome: from genetic basis to treatment. Neurology International, 2011, 1, .	0.5	1
212	Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2011, 58, 500-507.	1.9	163
213	Vagal stimulation for heart failure. Current Opinion in Cardiology, 2011, 26, 51-54.	1.8	8
214	Vagal Stimulation for Heart Diseases: From Animals to Men - An Example of Translational Cardiology -. Circulation Journal, 2011, 75, 20-27.	1.6	49
215	The Myth of QT Shortening by Weight Loss and Physical Training in Obese Subjects With Coronary Heart Disease. Obesity, 2011, 19, 200-203.	3.0	5
216	Pharmacological and non-pharmacological management of the congenital long QT syndrome: The rationale. , 2011, 131, 171-177.		22

#	Article	IF	Citations
217	Sympatheticâ€“parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Failure Reviews, 2011, 16, 101-107.	3.9	137
218	Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. Heart Failure Reviews, 2011, 16, 195-203.	3.9	151
219	Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. European Heart Journal, 2011, 32, 847-855.	2.2	444
220	QTc Behavior During Exercise and Genetic Testing for the Long-QT Syndrome. Circulation, 2011, 124, 2181-2184.	1.6	299
221	Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey. Clinical Cardiology, 2010, 33, 172-178.	1.8	13
222	Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome. American Journal of Cardiology, 2010, 105, 210-213.	1.6	28
223	The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation. American Journal of Cardiology, 2010, 105, 687-693.	1.6	98
224	Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?. Circulation, 2010, 122, 1272-1282.	1.6	261
225	Corrigendum to: 'Recommendations for interpretation of 12-lead electrocardiogram in the athlete' [Eur Heart J 2010;31:243-259]. European Heart Journal, 2010, 31, 379-379.	2.2	10
226	Repolarization Abnormalities in the Newborn. Journal of Cardiovascular Pharmacology, 2010, 55, 539-543.	1.9	13
227	Efficacy of left cardiac sympathetic denervation has an unforeseen side effect: Medicolegal complications. Heart Rhythm, 2010, 7, 1330-1332.	0.7	32
228	Recommendations for interpretation of 12-lead electrocardiogram in the athlete. European Heart Journal, 2010, 31, 243-259.	2.2	730
229	Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: The surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm, 2010, 7, 1161-1165.	0.7	88
230	Gain-of-function mutation S422L in the KCNJ8-encoded cardiac KATP channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm, 2010, 7, 1466-1471.	0.7	250
231	Congenital short QT syndrome. Indian Pacing and Electrophysiology Journal, 2010, 10, 86-95.	0.6	14
232	NOS1AP Is a Genetic Modifier of the Long-QT Syndrome. Circulation, 2009, 120, 1657-1663.	1.6	241
233	Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 652-659.	4.8	174
234	Prevalence of the Congenital Long-QT Syndrome. Circulation, 2009, 120, 1761-1767.	1.6	855

#	Article	IF	Citations
235	Excessive heart rate increase during mild mental stress in preparation for exercise predicts sudden death in the general population. European Heart Journal, 2009, 30, 1703-1710.	2.2	47
236	High Efficacy of Î²-Blockers in Long-QT Syndrome Type 1. Circulation, 2009, 119, 215-221.	1.6	274
237	Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy. Journal of the American College of Cardiology, 2009, 54, 832-837.	2.8	82
238	All LQT3 patients need an ICD: True or false?. Heart Rhythm, 2009, 6, 113-120.	0.7	91
239	Chronic vagal stimulation in patients with congestive heart failure. , 2009, 2009, 2037-9.		20
240	Cutting nerves and saving lives. Heart Rhythm, 2009, 6, 760-763.	0.7	53
241	Vagal stimulation for heart failure: Background and first in-man study. Heart Rhythm, 2009, 6, S76-S81.	0.7	54
242	A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome. Heart Rhythm, 2009, 6, 212-218.	0.7	41
243	Of founder populations, long QT syndrome, and destiny. Heart Rhythm, 2009, 6, S25-S33.	0.7	40
244	Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. Epilepsia, 2008, 49, 360-365.	5.1	74
245	Congenital long QT syndrome. Orphanet Journal of Rare Diseases, 2008, 3, 18.	2.7	213
246	Neural Control of Heart Rate Is an Arrhythmia Risk Modifier in Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 920-929.	2.8	99
247	Cardiac potassium channel dysfunction in sudden infant death syndrome. Journal of Molecular and Cellular Cardiology, 2008, 44, 571-581.	1.9	95
248	Chronic Vagus Nerve Stimulation (CVNS) - A New Target for Treatment of Congestive Heart Failure. Journal of Cardiac Failure, 2008, 14, S71-S72.	1.7	1
249	Prediction of unexpected sudden death among healthy dogs by a novel marker of autonomic neural activity. Heart Rhythm, 2008, 5, 300-305.	0.7	30
250	Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm, 2008, 5, 831-836.	0.7	65
251	Long QT syndrome, a purely electrical disease? Not anymore. European Heart Journal, 2008, 30, 253-255.	2.2	28
252	Left Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic Ventricular Tachycardia. New England Journal of Medicine, 2008, 358, 2024-2029.	27.0	377

#	Article	IF	Citations
253	Long-QT Syndrome After Age 40. Circulation, 2008, 117, 2192-2201.	1.6	134
254	Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome. Circulation, 2008, 117, 2184-2191.	1.6	255
255	Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failureâ˜†. European Journal of Heart Failure, 2008, 10, 550-555.	7.1	98
256	Long term vagal stimulation in patients with advanced heart failure First experience in man. European Journal of Heart Failure, 2008, 10, 884-891.	7.1	262
257	Malignant Perinatal Variant of Long-QT Syndrome Caused by a Profoundly Dysfunctional Cardiac Sodium Channel. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 370-378.	4.8	48
258	The Long QT Syndrome: A Clinical Counterpart of hERG Mutations. Novartis Foundation Symposium, 2008, , 186-203.	1.1	7
259	Ion channel diseases in children: manifestations and management. Current Opinion in Cardiology, 2008, 23, 184-191.	1.8	17
260	The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. Journal of Clinical Investigation, 2008, 118, 2219-29.	8.2	184
261	Abstract 2412: Chronic Vagus Nerve Stimulation in Patients with Chronic Heart Failure is Feasible and Appears Beneficial. Circulation, 2008, 118, .	1.6	4
262	Sudden Cardiac Death in Infancy: Focus on Prolonged Repolarization. , 2008, , 924-933.		1
263	Prevalence of Long-QT Syndrome Gene Variants in Sudden Infant Death Syndrome. Circulation, 2007, 115, 361-367.	1.6	472
264	From exercise training to sudden death prevention via adrenergic receptors. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2631-H2633.	3.2	3
265	Response to Letter Regarding Articles, â€œPrevalence of Long QT Syndrome Gene Variants in Sudden Infant Death Syndrome,â€•â€œCardiac Sodium Channel Dysfunction in Sudden Infant Death Syndrome,â€• and â€œContribution of Long-QT Syndrome Genes to Sudden Infant Death Syndrome: Is It Time to Consider Newborn Electrocardiographic Screening?â€• Circulation, 2007, 116, .	1.6	0
266	Cardiac Sodium Channel Dysfunction in Sudden Infant Death Syndrome. Circulation, 2007, 115, 368-376.	1.6	183
267	The Common Long-QT Syndrome Mutation KCNQ1/A341V Causes Unusually Severe Clinical Manifestations in Patients With Different Ethnic Backgrounds. Circulation, 2007, 116, 2366-2375.	1.6	157
268	Cardiac arrhythmias of genetic origin are important contributors to sudden infant death syndrome. Heart Rhythm, 2007, 4, 740-742.	0.7	8
269	Long QT Syndrome in Adults. Journal of the American College of Cardiology, 2007, 49, 329-337.	2.8	369
270	Long QT Syndrome and Pregnancy. Journal of the American College of Cardiology, 2007, 49, 1092-1098.	2.8	299

#	Article	IF	Citations
271	Baroreflex Sensitivity Predicts Long-Term Cardiovascular Mortality After Myocardial Infarction Even in Patients With Preserved Left Ventricular Function. Journal of the American College of Cardiology, 2007, 50, 2285-2290.	2.8	143
272	Newborn ECG screening to prevent sudden cardiac death. Heart Rhythm, 2006, 3, 1353-1355.	0.7	36
273	AB1-5. Heart Rhythm, 2006, 3, S2.	0.7	3
274	Cumulative Experience of Azimilide-Associated Torsades de Pointes Ventricular Tachycardia in the 19 Clinical Studies Comprising the Azimilide Database. Journal of the American College of Cardiology, 2006, 48, 471-477.	2.8	44
275	Does Pregnancy Increase Cardiac Risk for LQT1 Patients With the KCNQ1-A341V Mutation?. Journal of the American College of Cardiology, 2006, 48, 1410-1415.	2.8	56
276	The congenital long QT syndromes from genotype to phenotype: clinical implications. Journal of Internal Medicine, 2006, 259, 39-47.	6.0	201
277	Cost effectiveness of neonatal ECG screening for the long QT syndrome: reply. European Heart Journal, 2006, 28, 137-139.	2.2	4
278	Cost-effectiveness of neonatal ECG screening for the long QT syndrome. European Heart Journal, 2006, 27, 1824-1832.	2.2	121
279	The Jervell and Lange-Nielsen Syndrome. Circulation, 2006, 113, 783-790.	1.6	331
280	Psychological Stress Preceding Idiopathic Ventricular Fibrillation. Psychosomatic Medicine, 2005, 67, 359-365.	2.0	47
281	Electrocardiographic Features in Andersen-Tawil Syndrome Patients With KCNJ2 Mutations. Circulation, 2005, 111, 2720-2726.	1.6	248
282	Genetic Testing in the Long QT Syndrome. JAMA - Journal of the American Medical Association, 2005, 294, 2975.	7.4	413
283	KCNH2 -K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. Circulation, 2005, 112, 1251-1258.	1.6	228
284	Rapid Heart Rate Increase at Onset of Exercise Predicts Adverse Cardiac Events in Patients With Coronary Artery Disease. Circulation, 2005, 112, 1959-1964.	1.6	64
285	Management of long QT syndrome. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 346-351.	3.3	39
286	25th Anniversary of the International Long-QT Syndrome Registry. Circulation, 2005, 111, 1199-1201.	1.6	106
287	Phenotypic Variability and Unusual Clinical Severity of Congenital Long-QT Syndrome in a Founder Population. Circulation, 2005, 112, 2602-2610.	1.6	179
288	Heart-Rate Profile during Exercise as a Predictor of Sudden Death. New England Journal of Medicine, 2005, 352, 1951-1958.	27.0	875

#	Article	IF	Citations
289	The Long QT Syndrome. , 2005, , 665-680.		0
290	The long QT syndrome: a clinical counterpart of hERG mutations. Novartis Foundation Symposium, 2005, 266, 186-98; discussion 198-203.	1.1	2
291	Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome. Circulation, 2004, 109, 1826-1833.	1.6	600
292	Mortality in Patients After a Recent Myocardial Infarction. Circulation, 2004, 109, 990-996.	1.6	210
293	Stillbirths, Sudden Infant Deaths, and Long-QT Syndrome. Circulation, 2004, 109, 2930-2932.	1.6	52
294	Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With Î²-Blockers. JAMA - Journal of the American Medical Association, 2004, 292, 1341.	7.4	538
295	Prevalent Low-Frequency Oscillation of Heart Rate. Circulation, 2004, 110, 1183-1190.	1.6	77
296	Mortality due to sudden infant death syndrome in Northern Italy, 1990-2000: a baseline for the assessment of prevention campaigns. Paediatric and Perinatal Epidemiology, 2004, 18, 336-343.	1.7	9
297	The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction. Journal of the American College of Cardiology, 2004, 43, 1211-1216.	2.8	77
298	CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism. Cell, 2004, 119, 19-31.	28.9	1,403
299	Long QT Syndrome: Genotype-Phenotype Correlations. , 2004, , 651-659.		25
300	Prolonged Repolarization and Sudden Infant Death Syndrome. , 2004, , 711-719.		4
301	Risk Stratification in the Long-QT Syndrome. New England Journal of Medicine, 2003, 348, 1866-1874.	27.0	1,314
302	Counting Heart Beats:. Journal of Cardiovascular Electrophysiology, 2003, 14, 174-175.	1.7	1
303	Heterogeneous Regional Endocardial Repolarization is Associated with Increased Risk for Ischemiaâ€Dependent Ventricular Fibrillation after Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 2003, 14, 873-879.	1.7	22
304	Ambulatory Electrocardiogramâ€Based Tracking of T Wave Alternans in Postmyocardial Infarction Patients to Assess Risk of Cardiac Arrest or Arrhythmic Death. Journal of Cardiovascular Electrophysiology, 2003, 14, 705-711.	1.7	160
305	Location of Mutation in the KCNQ1 and Phenotypic Presentation of Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2003, 14, 1149-1153.	1.7	69
306	How Really Rare Are Rare Diseases?:. Journal of Cardiovascular Electrophysiology, 2003, 14, 1120-1121.	1.7	110

#	Article	IF	Citations
307	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology, 2003, 42, 103-109.	2.8	257
308	Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. International Journal of Cardiology, 2003, 90, 219-227.	1.7	32
309	Update of the guidelines on sudden cardiac death of the European Society of Cardiology. European Heart Journal, 2003, 24, 13-15.	2.2	135
310	Hemodynamic Effects of a New Inotropic Compound, PST-2744, in Dogs With Chronic Ischemic Heart Failure. Journal of Cardiovascular Pharmacology, 2003, 42, 169-173.	1.9	30
311	Combined Sodium and Calcium Channel Blockade in Prevention of Lethal Arrhythmias. Journal of Cardiovascular Pharmacology, 2003, 41, 665-670.	1.9	3
312	Prolonged Repolarization and Sudden Infant Death Syndrome. Contemporary Cardiology, 2003, , 481-496.	0.1	0
313	Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-goâ€“Related Gene Potassium Channel. Circulation, 2002, 105, 794-799.	1.6	370
314	Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes. Circulation, 2002, 105, 1943-1948.	1.6	514
315	Summary of Recommendations. Europace, 2002, 4, 3-18.	1.7	124
316	Exercise-Induced Increase in Baroreflex Sensitivity Predicts Improved Prognosis After Myocardial Infarction. Circulation, 2002, 106, 945-949.	1.6	269
317	Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. JAMA - Journal of the American Medical Association, 2002, 288, 701.	7.4	1,218
318	Erratum Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 2002, 23, 257.	2.2	2
319	Report from the Task Force of the European Society of Cardiology for the interpretation of the neonatal electrocardiogram. Cardiology in the Young, 2002, 12, 592-608.	0.8	5
320	Guidelines for the interpretation of the neonatal electrocardiogram. European Heart Journal, 2002, 23, 1329-1344.	2.2	184
321	Continental Europe triumph in golf competition. Lancet, The, 2002, 360, 468.	13.7	4
322	Heart rate turbulence-based predictors of fatal and nonfatal cardiac arrest (The autonomic tone and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	219
323	Electrocardiography first for reducing cot death. Lancet, The, 2001, 358, 672-673.	13.7	1
324	Molecular diagnosis in a child with sudden infant death syndrome. Lancet, The, 2001, 358, 1342-1343.	13.7	157

#	Article	IF	Citations
325	Pathophysiology and Prevention of Atrial Fibrillation. Circulation, 2001, 103, 769-777.	1.6	670
326	Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias. Circulation, 2001, 103, 2072-2077.	1.6	619
327	Electrocardiographic Prediction of Abnormal Genotype in Congenital Long QT Syndrome: Experience in 101 Related Family Members. Journal of Cardiovascular Electrophysiology, 2001, 12, 455-461.	1.7	79
328	Another Role for the Sympathetic Nervous System in the Long QT Syndrome?. Journal of Cardiovascular Electrophysiology, 2001, 12, 500-502.	1.7	37
329	QT Prolongation, Sudden Death, and Sympathetic Imbalance: The Pendulum Swings. Journal of Cardiovascular Electrophysiology, 2001, 12, 1074-1077.	1.7	37
330	Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 2001, 22, 1374-1450.	2.2	699
331	New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias. European Heart Journal, 2001, 22, 2148-2163.	2.2	15
332	Genotype-Phenotype Correlation in the Long-QT Syndrome. Circulation, 2001, 103, 89-95.	1.6	1,641
333	Clinical Implications for Affected Parents and Siblings of Probands With Long-QT Syndrome. Circulation, 2001, 104, 557-562.	1.6	71
334	New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias. Cardiovascular Research, 2001, 52, 345-360.	3.8	17
335	Clinical applicability of molecular biology: the case of the long QT syndrome. , 2000, 1, 88.		9
336	Evidence for a Cardiac Ion Channel Mutation Underlying Drugâ€Induced QT Prolongation and Lifeâ€Threatening Arrhythmias. Journal of Cardiovascular Electrophysiology, 2000, 11, 691-696.	1.7	312
337	Significance of QT dispersion in the long QT syndrome. Progress in Cardiovascular Diseases, 2000, 42, 345-350.	3.1	22
338	Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with the long QT syndrome. American Journal of Cardiology, 2000, 85, 457-461.	1.6	72
339	Mechanisms of I _{Ks} suppression in LQT1 mutants. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H3003-H3011.	3.2	68
340	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1748-H1756.	3.2	88
341	A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10613-10618.	7.1	466
342	Effectiveness and Limitations of Î²-Blocker Therapy in Congenital Long-QT Syndrome. Circulation, 2000, 101, 616-623.	1.6	783

#	Article	IF	Citations
343	Spectrum of ST-Tâ€“Wave Patterns and Repolarization Parameters in Congenital Long-QT Syndrome. Circulation, 2000, 102, 2849-2855.	1.6	409
344	Comparison between invasive and non-invasive measurements of baroreflex sensitivity. Implications for studies on risk stratification after a myocardial infarction. European Heart Journal, 2000, 21, 1522-1529.	2.2	39
345	A Molecular Link between the Sudden Infant Death Syndrome and the Long-QT Syndrome. New England Journal of Medicine, 2000, 343, 262-267.	27.0	340
346	QT or Not QT?. New England Journal of Medicine, 2000, 343, 352-356.	27.0	22
347	Clinical and Genetic Heterogeneity of Right Bundle Branch Block and ST-Segment Elevation Syndrome. Circulation, 2000, 102, 2509-2515.	1.6	490
348	Spectrum of Mutations in Long-QT Syndrome Genes. Circulation, 2000, 102, 1178-1185.	1.6	1,157
349	The Elusive Link Between LQT3 and Brugada Syndrome. Circulation, 2000, 102, 945-947.	1.6	243
350	Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone. Journal of the American College of Cardiology, 2000, 35, 1263-1275.	2.8	104
351	Task Force Report:The legal implications of medical guidelinesâ€” a Task Force of the European Society of Cardiology. European Heart Journal, 1999, 20, 1152-1157.	2.2	46
352	Gene-specific lethality of arrhythmic events in the long QT syndrome? A message from the International Registry. European Heart Journal, 1999, 20, 1137-1139.	2.2	2
353	Homozygous Deletion in KVLQT1 Associated With Jervell and Lange-Nielsen Syndrome. Circulation, 1999, 99, 1344-1347.	1.6	80
354	Cellular Dysfunction of LQT5-MinK Mutants: Abnormalities of IKs, IKr and Trafficking in Long QT Syndrome. Human Molecular Genetics, 1999, 8, 1499-1507.	2.9	170
355	Genetic and molecular basis of cardiac arrhythmias Impact on clinical management. European Heart Journal, 1999, 20, 174-195.	2.2	134
356	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Part III. Circulation, 1999, 99, 674-681.	1.6	131
357	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II. Circulation, 1999, 99, 518-528.	1.6	295
358	Two-to-One AV Block Associated with the Congenital Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 1999, 10, 108-113.	1.7	22
359	Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. American Journal of Cardiology, 1999, 84, 876-879.	1.6	219
360	Low Penetrance in the Long-QT Syndrome. Circulation, 1999, 99, 529-533.	1.6	783

#	Article	IF	Citations
361	SEVERE CHRONIC STRESS OFTEN PRECEDES IDIOPATHIC VENTRICULAR FIBRILLATION (IVF). Psychosomatic Medicine, 1999, 61, 113-114.	2.0	0
362	The ATRAMI Prospective Study: Implications for Risk Stratification after Myocardial Infarction. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 38-40.	1.0	1
363	The Long QT Syndrome. Annals of Noninvasive Electrocardiology, 1998, 3, 63-73.	1.1	28
364	Mortality in the Survival With ORal D-Sotalol (SWORD) Trial: Why Did Patients Die? 11This work was supported by a grant from Bristol-Myers Squibb, Princeton, New Jersey.. American Journal of Cardiology, 1998, 81, 869-876.	1.6	150
365	Do Animal Models Have Clinical Value?. American Journal of Cardiology, 1998, 81, 14D-20D.	1.6	32
366	Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet, The, 1998, 351, 478-484.	13.7	2,791
367	Influence of Pregnancy on the Risk for Cardiac Events in Patients With Hereditary Long QT Syndrome. Circulation, 1998, 97, 451-456.	1.6	235
368	Prolongation of the QT Interval and the Sudden Infant Death Syndrome. New England Journal of Medicine, 1998, 338, 1709-1714.	27.0	672
369	New Mutations in the KVLQT1 Potassium Channel That Cause Long-QT Syndrome. Circulation, 1998, 97, 1264-1269.	1.6	87
370	Influence of the Genotype on the Clinical Course of the Long-QT Syndrome. New England Journal of Medicine, 1998, 339, 960-965.	27.0	728
371	A Recessive Variant of the Romano-Ward Long-QT Syndrome?. Circulation, 1998, 97, 2420-2425.	1.6	139
372	Age- and Sex-Related Differences in Clinical Manifestations in Patients With Congenital Long-QT Syndrome. Circulation, 1998, 97, 2237-2244.	1.6	451
373	Serotonin 1A Receptors, Melatonin, and the Proportional Control Thermostat in Patients With Winter Depression. Archives of General Psychiatry, 1998, 55, 897.	12.3	20
374	Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). European Heart Journal, 1998, 19, 85-95.	2.2	47
375	Antifibrillatory efficacy of ersentilide, a novel Î²-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. Cardiovascular Research, 1998, 40, 56-63.	3.8	12
376	ATRAMI: a mark in the quest for the prognostic value of autonomic markers. European Heart Journal, 1998, 19, 1593-1595.	2.2	64
377	Long QT Genotype Can Be Identified by ECG Phenotype. Journal of the American College of Cardiology, 1998, 31, 192A.	2.8	1
378	Variable Phenotype of Long QT Syndrome Patients With the Same Genetic Defect. Journal of the American College of Cardiology, 1998, 31, 349A.	2.8	0

#	Article	IF	Citations
379	ECG Repolarization Parameters in LQTS Family Members With Borderline QTc Duration and Cardiac Events. Journal of the American College of Cardiology, 1998, 31, 193A.	2.8	0
380	Cardiac Events in Genotyped Long QT Syndrome Patients. Journal of the American College of Cardiology, 1998, 31, 349A.	2.8	0
381	Prevalence of the Bifid T Waves in Genotyped LQTS Children. Journal of the American College of Cardiology, 1998, 31, 193A.	2.8	0
382	Effects of Î²-adrenergic blockade on dispersion of ventricular repolarization in newborn infants with prolonged QT interval. American Heart Journal, 1997, 134, 406-410.	2.7	20
383	QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. American Heart Journal, 1997, 133, 108-111.	2.7	43
384	Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet, The, 1997, 349, 667-674.	13.7	1,041
385	Age-Gender Influence on the Rate-Corrected QT Interval and the QT-Heart Rate Relation in Families With Genotypically Characterized Long QT Syndrome. Journal of the American College of Cardiology, 1997, 29, 93-99.	2.8	177
386	Impaired Baroreflex Sensitivity Is Correlated With Hemodynamic Deterioration of Sustained Ventricular Tachycardia. Journal of the American College of Cardiology, 1997, 29, 568-575.	2.8	59
387	Time- and Rate-Dependent Alterations of the QT Interval Precede the Onset of Torsade de Pointes in Patients With Acquired QT Prolongation fn1fn1This work was performed during Dr. Gilmourâ€™s sabbatical leave in the laboratory of Dr. Schwartz.. Journal of the American College of Cardiology, 1997, 30, 209-217.	2.8	49
388	Molecular Biology of the Long QT Syndrome: Impact on Management. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2052-2057.	1.2	40
389	Baroreflex Sensitivity as a Cardiac and Arrhythmia Mortality Risk Stratifier. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2602-2613.	1.2	35
390	The long QT syndrome. Current Problems in Cardiology, 1997, 22, 297-351.	2.4	259
391	Evaluation of the Spatial Aspects of T-Wave Complexity in the Long-QT Syndrome. Circulation, 1997, 96, 3006-3012.	1.6	151
392	Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet, The, 1996, 348, 7-12.	13.7	1,345
393	Muscarinic Effects on Action Potential Duration and its Rate Dependence in Canine Purkinje Fibers. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 2023-2026.	1.2	7
394	Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics, 1996, 12, 17-23.	21.4	1,663
395	Patency of Infarct-Related Artery. Circulation, 1996, 93, 1114-1122.	1.6	59
396	Multiple Mechanisms in the Long-QT Syndrome. Circulation, 1996, 94, 1996-2012.	1.6	543

#	Article	IF	Citations
397	Multiple Mechanisms of Na ⁺ Channelâ€“ Linked Long-QT Syndrome. Circulation Research, 1996, 78, 916-924.	4.5	285
398	Differential Response to Na ⁺ Channel Blockade, Î²-Adrenergic Stimulation, and Rapid Pacing in a Cellular Model Mimicking the SCN5A and HERG Defects Present in the Long-QT Syndrome. Circulation Research, 1996, 78, 1009-1015.	4.5	148
399	Use of baroreceptor reflex sensitivity in the prediction of risk after myocardial infarction. Developments in Cardiovascular Medicine, 1996, , 77-91.	0.1	0
400	K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic Activity. Journal of Cardiovascular Pharmacology, 1995, 26, 847-854.	1.9	21
401	Survival with oral d-Sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial). American Journal of Cardiology, 1995, 75, 1023-1027.	1.6	116
402	Are gender differences in QTc present at birth?. American Journal of Cardiology, 1995, 75, 1277-1278.	1.6	105
403	Baroreflex Sensitivity. Journal of Cardiovascular Electrophysiology, 1995, 6, 761-774.	1.7	63
404	Left Cardiac Sympathetic Denervation in Long QT Syndrome Patients. Journal of Interventional Cardiology, 1995, 8, 776-781.	1.2	11
405	Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Human Molecular Genetics, 1995, 4, 1603-1607.	2.9	316
406	Effects of the potassium channel blocking agent ambasilide on ventricular arrhythmias induced by acute myocardial ischemia and sympathetic activation. American Heart Journal, 1995, 129, 549-556.	2.7	7
407	Baroreflex sensitivity, but not heart rate variability, is reduced in patients with life-threatening ventricular arrhythmias long after myocardial infarction. American Heart Journal, 1995, 130, 473-480.	2.7	83
408	Sympathetic activation, ventricular repolarization and Ikrblockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents. Journal of the American College of Cardiology, 1995, 25, 1609-1614.	2.8	43
409	746-1 Antifibrillatory Effect of HE-93, a New K + Channel and Î² Adrenergic Blocker in Conscious Dogs with a Healed Myocardial Infarction. Journal of the American College of Cardiology, 1995, 25, 188A-189A.	2.8	1
410	Do Increases in Markers of Vagal Activity Imply Protection From Sudden Death?. Circulation, 1995, 91, 2516-2519.	1.6	70
411	ECG T-Wave Patterns in Genetically Distinct Forms of the Hereditary Long QT Syndrome. Circulation, 1995, 92, 2929-2934.	1.6	501
412	Long QT Syndrome Patients With Mutations of the SCN5A and HERG Genes Have Differential Responses to Na ⁺ Channel Blockade and to Increases in Heart Rate. Circulation, 1995, 92, 3381-3386.	1.6	689
413	Alpha1-Adrenergic Blockade and Sudden Cardiac Death. Journal of Cardiovascular Electrophysiology, 1994, 5, 76-89.	1.7	10
414	Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nature Genetics, 1994, 8, 141-147.	21.4	263

#	Article	IF	Citations
415	Modulation of the Electrical Restitution of Canine Purkinje Fibers by Local Anesthetic Drugs: A Study with Flecainide and Propafenone. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2074-2078.	1.2	2
416	Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. Journal of the American College of Cardiology, 1994, 23, 296-301.	2.8	177
417	Malignant arrhythmias and acute myocardial ischemia: Interaction between flecainide and the autonomic nervous system. American Heart Journal, 1994, 128, 973-982.	2.7	15
418	A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. Journal of Affective Disorders, 1994, 32, 197-200.	4.1	20
419	Torsade de Pointes. Drugs, 1994, 47, 51-65.	10.9	122
420	The European Myocardial Infarct Amiodarone Trial (EMIAT). American Journal of Cardiology, 1993, 72, F95-F98.	1.6	60
421	Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. Journal of the American College of Cardiology, 1993, 22, 1327-1334.	2.8	91
422	Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. Journal of the American College of Cardiology, 1993, 22, 283-290.	2.8	85
423	Parasympathetic control of cycle length dependence of endocardial ventricular repolarisation in the intact feline heart during steady state conditions. Cardiovascular Research, 1993, 27, 823-827.	3.8	12
424	Pathophysiological mechanisms of sudden infant death syndrome. Cardiology in the Young, 1992, 2, 272-276.	0.8	4
425	The Sicilian Gambit: a response to Drs Colatsky and Harrison. Cardiovascular Research, 1992, 26, 568-570.	3.8	3
426	Prevention of Sudden Cardiac Death After a First Myocardial Infarction by Pharmacologic or Surgical Antiadrenergic Interventions. Journal of Cardiovascular Electrophysiology, 1992, 3, 2-16.	1.7	162
427	Idiopathic Long QT Syndrome Exacerbated by Beta-Adrenergic Blockade and Responsive to Left Cardiac Sympathetic Denervation: Implications Regarding Electrophysiologic Substrate and Adrenergic Modulation. Journal of Cardiovascular Electrophysiology, 1992, 3, 295-305.	1.7	18
428	Ionic Mechanisms Determining the Timing of Ventricular Repolarization: Significance for Cardiac Arrhythmias. Annals of the New York Academy of Sciences, 1992, 644, 1-22.	3.8	28
429	Cellular Mechanisms of Early Afterdepolarizations. Annals of the New York Academy of Sciences, 1992, 644, 23-32.	3.8	77
430	Multiple Ionic Mechanisms of Early Afterdepolarizations in Isolated Ventricular Myocytes from Guinea-pig Hearts. Annals of the New York Academy of Sciences, 1992, 644, 33-47.	3.8	23
431	Mechanistic and Clinical Aspects of Acquired Long QT Syndromes. Annals of the New York Academy of Sciences, 1992, 644, 48-56.	3.8	7
432	Acquired Long QT Syndrome due to Antiarrhythmic Drugs and Bradyarrhythmias. Annals of the New York Academy of Sciences, 1992, 644, 57-73.	3.8	14

#	Article	IF	Citations
433	Experimental QT Interval Prolongation. Annals of the New York Academy of Sciences, 1992, 644, 74-83.	3.8	5
434	A Cellular Basis for the Prolonged QT Interval in Mammals. Annals of the New York Academy of Sciences, 1992, 644, 84-92.	3.8	6
435	Torsades de Pointes and Ventricular Fibrillation in a Canine Model of Quinidine-induced QT Prolongation. Annals of the New York Academy of Sciences, 1992, 644, 93-102.	3.8	8
436	Clinical Aspects of the Idiopathic Long QT Syndrome. Annals of the New York Academy of Sciences, 1992, 644, 103-111.	3.8	24
437	Pathogenesis and Therapy of the Idiopathic Long QT Syndrome. Annals of the New York Academy of Sciences, 1992, 644, 112-141.	3.8	36
438	Sex Differences in Phenotypic Manifestation and Gene Transmission in the Romano-Ward Syndrome. Annals of the New York Academy of Sciences, 1992, 644, 142-156.	3.8	37
439	A New Look at Torsades de Pointes. Annals of the New York Academy of Sciences, 1992, 644, 157-177.	3.8	21
440	Induction of TU Abnormalities in Patients with Torsades de Pointes. Annals of the New York Academy of Sciences, 1992, 644, 178-186.	3.8	3
441	Controlling Cardiac Arrhythmias by Lengthening Repolarization: Rationale from Experimental Findings and Clinical Considerations. Annals of the New York Academy of Sciences, 1992, 644, 187-209.	3.8	29
442	Effects of Amiodarone and Bepridil on Ventricular Depolarization and Repolarization. Annals of the New York Academy of Sciences, 1992, 644, 210-222.	3.8	6
443	Class III Drugs: Their Effects on Arrhythmias and on the QT Interval. Annals of the New York Academy of Sciences, 1992, 644, 223-234.	3.8	0
444	Efficacy and Safety of Amiodarone in Treatment of Refractory Atrial and Ventricular Tachyarrhythmias. Annals of the New York Academy of Sciences, 1992, 644, 235-245.	3.8	2
445	Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. American Heart Journal, 1992, 124, 883-890.	2.7	53
446	Dispersion of ventricular repolarization in the long QT syndrome. American Journal of Cardiology, 1991, 68, 614-620.	1.6	80
447	Effect of reflex vagal activation on frequency of ventricular premature complexes. American Journal of Cardiology, 1991, 68, 349-354.	1.6	25
448	Cardiac Pain, Sympathetic Afferents, and Life-Threatening Arrhythmias. Journal of Cardiovascular Electrophysiology, 1991, 2, s100-s113.	1.7	5
449	Electrophysiologic mechanisms involved in the development of torsades de pointes. Cardiovascular Drugs and Therapy, 1991, 5, 203-212.	2.6	19
450	Sympathetic â€" Parasympathetic Interaction and Sudden Death. , 1991, 85 Suppl 1, 305-321.		34

#	Article	IF	Citations
451	Autonomic Nervous System and Arrhythmias. Annals of the New York Academy of Sciences, 1990, 601, 247-262.	3.8	20
452	Postnatal development of cardiac innervation and susceptibility to malignant arrhythmias in the dog. Journal of the Autonomic Nervous System, 1990, 30, S153-S154.	1.9	4
453	Heart rate variability before and after myocardial infarction in conscious dogs at high and low risk of sudden death. Journal of the American College of Cardiology, 1990, 16, 978-985.	2.8	134
454	Tocainide and mortality after myocardial infarction: A prospective study in conscious dogs. Journal of the American College of Cardiology, 1990, 16, 1475-1480.	2.8	3
455	Denervation of the heart in congenital long QT and deafness. American Journal of Cardiology, 1989, 64, 424.	1.6	1
456	Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-up. American Heart Journal, 1989, 117, 1258-1264.	2.7	7
457	Carbon monoxide and lethal arrhythmias in conscious dogs with a healed myocardial infarction. American Heart Journal, 1989, 117, 348-357.	2.7	12
458	Comparison of baroreflex sensitivity and heart period variability after myocardial infarction. Journal of the American College of Cardiology, 1989, 14, 1511-1518.	2.8	183
459	Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: Effect of nifedipine. American Heart Journal, 1988, 116, 37-43.	2.7	24
460	Demonstration of a different sensitivity to epinephrine in isolated and in vivo hearts. European Journal of Pharmacology, 1988, 156, 87-94.	3.5	3
461	Role of the autonomic nervous system in reperfusion arrhythmias. Journal of Molecular and Cellular Cardiology, 1988, 20, 113-118.	1.9	13
462	Cardiac Innervation, Neonatal Electrocardiography, and SIDS.. Annals of the New York Academy of Sciences, 1988, 533, 210-220.	3.8	46
463	Baroreflex Sensitivity and Its Evolution During the First Year After Myocardial Infarction. Journal of the American College of Cardiology, 1988, 12, 629-636.	2.8	155
464	The Role of Left Stellectomy in the Prevention of Lethal Arrhythmias. Developments in Cardiovascular Medicine, 1988, , 109-121.	0.1	1
465	The Influence of the Autonomic Nervous System on Sudden Cardiac Death. Cardiology, 1987, 74, 297-309.	1.4	14
466	Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing. American Journal of Cardiology, 1987, 60, 1068-1072.	1.6	14
467	Efficacy of diltiazem in two experimental feline models of sudden cardiac death. Journal of the American College of Cardiology, 1986, 8, 661-668.	2.8	29
468	Mexiletine in the Prevention of Sudden Cardiac Death: Experimental Evaluation and Clinical Implications. Clinical Progress in Electrophysiology and Pacing, 1986, 4, 595-601.	0.1	0

#	Article	IF	Citations
469	Role of the Autonomic Nervous System in the Genesis of Early Ischemic Arrhythmias. Journal of Cardiovascular Pharmacology, 1985, 7, S8-S12.	1.9	25
470	Comparative Evaluation of Antiarrhythmic Therapy. Drugs, 1985, 29, 86.	10.9	0
471	Lack of correlation between occlusion and reperfusion arrhythmias in the cat. American Heart Journal, 1985, 109, 932-936.	2.7	11
472	The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. American Heart Journal, 1985, 109, 937-948.	2.7	113
473	Idiopathic long QT syndrome: Progress and questions. American Heart Journal, 1985, 109, 399-411.	2.7	605
474	Effect of ventricular fibrillation complicating acute myocardial infarction on long-term prognosis: Importance of the site of infarction. American Journal of Cardiology, 1985, 56, 384-389.	1.6	36
475	THE RATIONALE AND THE ROLE OF LEFT STELLECTOMY FOR THE PREVENTION OF MALIGNANT ARRHYTHMIAS. Annals of the New York Academy of Sciences, 1984, 427, 199-221.	3.8	98
476	Neural Factors in Sudden Death. , 1984, , 467-471.		0
477	T-Wave Amplitude as an Index of Cardiac Sympathetic Activity: A Misleading Concept. Psychophysiology, 1983, 20, 696-701.	2.4	42
478	The Idiopathic Long Q-T Syndrome. Annals of Internal Medicine, 1983, 99, 561.	3.9	33
479	Left stellectomy and denervation supersensitivity in conscious dogs. American Journal of Cardiology, 1982, 49, 1185-1190.	1.6	37
480	THE ROLE OF THE AUTONOMIC NERVOUS SYSTEM IN SUDDEN CORONARY DEATH. Annals of the New York Academy of Sciences, 1982, 382, 162-180.	3.8	141
481	Cardiac Arrhythmias Elicited by Interaction Between Acute Myocardial Ischemia and Sympathetic Hyperactivity. Journal of Cardiovascular Pharmacology, 1981, 3, 1251-1259.	1.9	109
482	Neural mechanisms in life-threatening arrhythmias. American Heart Journal, 1980, 100, 705-715.	2.7	181
483	Sudden death and the idiopathic long Q-T syndrome. American Journal of Medicine, 1979, 66, 6-7.	1.5	111
484	Sudden infant death, long Q-T interval and long Q-T syndrome. American Journal of Medicine, 1977, 62, 164.	1.5	0
485	Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. American Journal of Cardiology, 1976, 37, 1034-1040.	1.6	319
486	Cardiac sympathetic innervation and the sudden infant death syndrome. American Journal of Medicine, 1976, 60, 167-172.	1.5	207

#	Article	IF	Citations
487	Effects of unilateral stellate ganglion blockade on the arrhythmias associated with coronary occlusion. American Heart Journal, 1976, 92, 589-599.	2.7	174
488	Spinal cardiovascular reflexes. Brain Research, 1975, 87, 239-246.	2.2	54
489	Electrical alternation of the T-wave: Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. American Heart Journal, 1975, 89, 45-50.	2.7	504
490	The long Q-T syndrome. American Heart Journal, 1975, 89, 378-390.	2.7	911
491	Reflex Hemodynamic Responses Initiated from the Thoracic Aorta. Circulation Research, 1974, 34, 78-84.	4.5	43
492	Reflex responses of sympathetic preganglionic neurones initiated by different cardiovascular receptors in spinal animals. Brain Research, 1974, 68, 215-225.	2.2	72
493	Nervous activity of afferent cardiac sympathetic fibres with atrial and ventricular endings. Journal of Physiology, 1973, 229, 457-469.	2.9	268
494	A Cardiocardiac Sympathovagal Reflex in the Cat. Circulation Research, 1973, 32, 215-220.	4.5	260
495	A cardiac murmur depending on the Wolff-Parkinson-White syndrome. American Heart Journal, 1972, 83, 532-534.	2.7	1
496	Reflex changes in cardiac vagal efferent nervous activity elicited by stimulation of afferent fibres in the cardiac sympathetic nerves. Brain Research, 1972, 42, 482-485.	2.2	17
497	Tonic afferent sympathetic activity from the heart. Experientia, 1972, 28, 269-270.	1.2	13
498	Activation of cardiac vagal receptors during myocardial ischemia. Experientia, 1971, 27, 1423-1424.	1.2	55
499	Evidence for a spinal sympathetic regulation of cardiovascular functions. Experientia, 1970, 26, 965-966.	1.2	8
500	Reflex activity of single preganglionic sympathetic fibres during coronary occlusion. Experientia, 1969, 25, 152-153.	1.2	12
501	Autonomic Nervous System: Emerging Concepts and Clinical Applications. , 0, , 62-73.		0
502	Frequency Domain Heart Period and QT Interval Variability Markers Are Linked to Arrhythmic Risk in Long QT Syndrome Type 2. , 0, , .		0